Cambridge Healthtech Institute’s 3rd Annual

Combination Cancer Immunotherapy

Rational Combination Strategies to Improve Efficacy and Reduce Resistance

June 18-19, 2019

 

The future of immuno-oncology drug development is positioned in combination therapies, where immunotherapy modalities are tested in rational combinations with other immunotherapies or targeted therapies for synergistic effects. Combination immunotherapy promises to deliver long-term survival benefits that may be unavailable with current approaches. CHI’s 3rd Annual Combination Cancer Immunotherapy conference will explore the most effective combinations of immunotherapy with conventional cancer therapy, other immunotherapy, or targeted therapy. Coverage will include understanding the mechanism of action, managing toxicity, strategies to design synergistic combinations, biomarker development and case studies of ongoing combination immunotherapy studies from the leading researchers in industry and academia.

RATIONAL COMBINATION CANCER IMMUNOTHERAPY

Immunotherapy Combinations: Friends or Foes
Rakesh Dixit, PhD, DABT, Vice President, R&D; Global Head Biologics Safety Assessment, MedImmune

Why Are We So Late in Treatment of Breast Cancer Using ICI?
Stefan Glueck, MD, PhD, FRCPC, Professor of Medicine, Vice President, GMA Early Assets, Celgene Corporation

T Cell Dysfunction in Cancer and Combination Immunotherapy
Dimitris Skokos, PhD, Associate Director, Immune & Inflammatory Diseases, Regeneron Pharmaceuticals 

BISPECIFIC ANTIBODIES FOR COMBINATION IMMUNOTHERAPY 

Bispecifics to the Rescue: Enabling T Cell Activation in Immune Deserts
Raphael Clynes, MD, PhD, Vice President, Translational Biology, Xencor

Leveraging Bispecific Molecules for Combination Immunotherapy of Cancer
Jon Wigginton, MD, Senior Vice President, Clinical Development & CMO, MacroGenics


For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com

For partnering and sponsorship information, please contact:

Companies A-K
Rod Eymael
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-247-6286
Email:  reymael@healthtech.com

Companies L-Z
Joseph Vacca, M.S.
Director, Business Development
Cambridge Healthtech InstitutePhone: 781-972-5431
Email: jvacca@healthtech.com